Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study probes why GI cancer strikes the young

NCT ID NCT07479472

Knowledge-focused Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at 150 adults aged 18-49 who are newly diagnosed with early-onset gastrointestinal cancer. Researchers will collect information on the cancer's features, patients' lifestyle habits, and how the disease progresses over 12 months. The goal is to better understand this type of cancer in younger people, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Apr 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients will be selected and recruited during routine medical appointments by specialized medical oncologists at the participating cancer center. Patients will be enrolled consecutively based on inclusion and exclusion criteria

Ages

18 to 49 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Provide a signed and dated informed consent form (ICF) * Willing to comply with all study procedures and be available for the duration of the study * Male or female, aged 18-49 years old at time of EoGI cancer diagnosis * Patients with newly diagnosed early-onset gastrointestinal cancer histologically confirmed: colorectal, gastroesophageal and pancreatic tumor site, regardless of histological type * Any disease stage, performance status, and type of treatment, including experimental therapies and supportive care * Previous or concomitant malignancies are allowed provided they do not involve the gastrointestinal tract Exclusion Criteria: * Cognitive, linguistic, or physical barriers that prevent a detailed reconstruction of the patient's personal medical history including past lifestyle habits * Having previously received any treatments directed at the newly diagnosed EOGI cancer (i.e., at the time of inclusion, the patient has not yet started any type of treatment, excluding surgery)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Early-onset gastrointestinal cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Early-onset gastrointestinal cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centro Oncologico Modenese, Azienda Policlinico Universitaria di Modena

    Modena, MO, Italy

  • Istituto Romagnolo per lo studio dei tumori "Dino Amadori", IRCCS IRST

    Meldola, FC, Italy

  • Oncologia Area Sud Ausl Modena

    Sassuolo, MO, Italy

  • Oncologia Medica, AUSL Piacenza

    Piacenza, PC, Italy

  • Oncologia Medica, CORE Azienda USL-IRCCS Reggio Emilia

    Reggio Emilia, RE, Italy

  • Oncologia Ospedale Carlo Poma di Mantova

    Mantua, MN, Italy

  • Oncologia di Prossimità, Ospedale di Carpi e DHO Mirandola, Ausl Modena

    Carpi, MO, Italy

  • Oncologia, ASST SETTE LAGHI, Ospedale di Circolo

    Varese, VA, Italy

  • Oncologia, Azienda Ospedaliero Universitaria di Parma

    Parma, PR, Italy

  • Oncologia, Ospedale Sant'Orsola

    Bologna, BO, Italy

  • Oncologia, Ospedale di Rimini

    Rimini, RN, Italy